이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Enzo Biochem 관리

관리 기준 확인 0/4

Enzo Biochem's CEO는 Kara Cannon, Sep2023 에 임명되었습니다 의 임기는 1년 미만입니다. 총 연간 보상은 $ 1.22M, 24.4% 로 구성됩니다. 24.4% 급여 및 75.6% 보너스(회사 주식 및 옵션 포함). 는 $ 311.29K 가치에 해당하는 회사 주식의 0.54% 직접 소유합니다. 311.29K. 경영진과 이사회의 평균 재임 기간은 각각 1 년과 1.8 년입니다.

주요 정보

Kara Cannon

최고 경영자

US$1.2m

총 보상

CEO 급여 비율	24.4%
CEO 임기	less than a year
CEO 소유권	0.5%
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	less than a year

최근 관리 업데이트

Recent updates

If You Had Bought Enzo Biochem's (NYSE:ENZ) Shares Three Years Ago You Would Be Down 66%

Jan 08

Enzo Biochem nabs expanded EUA nod for testing of COVID samples

Jan 04

Enzo Biochem: Betting On The Activists Now

Dec 16

Here's What We Think About Enzo Biochem's (NYSE:ENZ) CEO Pay

Dec 13

CEO 보상 분석

Kara Cannon 의 보수는 Enzo Biochem 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Apr 30 2024	n/a	n/a	-US$18m
Jan 31 2024	n/a	n/a	-US$23m
Oct 31 2023	n/a	n/a	-US$25m
Jul 31 2023	US$1m	US$299k	-US$25m
Apr 30 2023	n/a	n/a	-US$27m
Jan 31 2023	n/a	n/a	-US$24m
Oct 31 2022	n/a	n/a	-US$23m
Jul 31 2022	US$769k	US$270k	-US$20m
Apr 30 2022	n/a	n/a	-US$7m
Jan 31 2022	n/a	n/a	US$300k
Oct 31 2021	n/a	n/a	US$5m
Jul 31 2021	US$426k	US$265k	US$8m
Apr 30 2021	n/a	n/a	US$1m
Jan 31 2021	n/a	n/a	-US$11m
Oct 31 2020	n/a	n/a	-US$21m
Jul 31 2020	US$371k	US$220k	-US$29m
Apr 30 2020	n/a	n/a	-US$31m
Jan 31 2020	n/a	n/a	US$2m
Oct 31 2019	n/a	n/a	US$822k
Jul 31 2019	US$379k	US$220k	US$2m
Apr 30 2019	n/a	n/a	US$2m
Jan 31 2019	n/a	n/a	-US$23m
Oct 31 2018	n/a	n/a	-US$16m
Jul 31 2018	US$342k	US$198k	-US$10m

보상 대 시장: Kara 의 총 보상 ($USD 1.22M )은 US 시장( $USD 681.57K ).

보상과 수익: 회사가 수익성이 없는 동안 Kara 의 보상이 증가했습니다.

CEO

Kara Cannon (55 yo)

less than a year

테뉴어

US$1,221,793

보상

Ms. Kara Cannon serves as Chief Executive Officer at Enzo Biochem, Inc. from January 31, 2024 and serves as its Director from 2024 and served as its Interim CEO since September 5, 2023 until January 31, 20...

리더십 팀

이름	위치	테뉴어	보상	소유권
Kara Cannon	CEO & Director	less than a year	US$1.22m	0.54% $ 314.0k
Patricia Eckert	Chief Financial Officer	1.8yrs	US$453.56k	0.038% $ 22.1k
Brian Fisher	General Counsel	less than a year	데이터 없음	데이터 없음

1.0yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 관리: ENZ 의 관리팀은 경험 (평균 재직 기간 1 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Kara Cannon	CEO & Director	less than a year	US$1.22m	0.54% $ 314.0k
Steven Pully	Independent Chairperson of the Board	less than a year	데이터 없음	0.034% $ 20.2k
Bradley Radoff	Independent Director	2.7yrs	US$195.00k	8.19% $ 4.8m

0.9yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 이사회: ENZ 의 이사회는 경험(평균 재직 기간 1.7 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Enzo Biochem 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

High number of new and inexperienced directors

Enzo Biochem, Inc. Appoints Kara Cannon to Serve as the Chief Executive Officer

Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2024

Enzo Biochem, Inc. Appoints Steven J. Pully to its Board of Directors

High number of new and inexperienced directors

Enzo Biochem, Inc. Announces CEO Changes

Recent updates

High number of new and inexperienced directors

Enzo Biochem: Is This Time Finally Different?

Third quarter 2024 earnings released: US$0.042 loss per share (vs US$0.31 loss in 3Q 2023)

Second quarter 2024 earnings released: US$0.017 loss per share (vs US$0.059 loss in 2Q 2023)

Enzo Biochem, Inc. Appoints Kara Cannon to Serve as the Chief Executive Officer

Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2024

Enzo Biochem, Inc. announced delayed annual 10-K filing

Enzo Biochem, Inc. Appoints Steven J. Pully to its Board of Directors

Enzo Biochem: Cleaned Up And Cash-Rich But Unloved

High number of new and inexperienced directors

Enzo Biochem, Inc. Announces CEO Changes

Is Enzo Biochem (NYSE:ENZ) Using Debt Sensibly?

Enzo Biochem, Inc. Provides Earnings Guidance for the Years 2023, 2024, 2025, 2026 and 2027

Second quarter 2023 earnings released: US$0.23 loss per share (vs US$0.055 loss in 2Q 2022)

Is Enzo Biochem (NYSE:ENZ) A Risky Investment?

First quarter 2023 earnings released: US$0.22 loss per share (vs US$0.048 loss in 1Q 2022)

Enzo Biochem Non-GAAP EPS of -$0.18, revenue of $18.28M

Enzo Biochem, Inc. to Report Q1, 2023 Results on Dec 12, 2022

CEO & Director recently bought US$197k worth of stock

Insider recently bought US$5.0m worth of stock

High number of new and inexperienced directors

Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2023

Enzo Biochem, Inc. Announces Resignation of David Bench as Senior Vice President, Treasurer and Corporate Secretary, Effective November 14, 2022

Enzo Biochem appoints Patricia Eckert as interim CFO

Full year 2022 earnings released

Enzo Biochem Non-GAAP EPS of -$0.17, revenue of $20.28M

Enzo Biochem, Inc. to Report Q4, 2022 Results on Oct 14, 2022

Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?

Enzo Biochem, Inc. Launches Ampiview Gene Expression Platform with First Products Targeting Detection of HPV and Sars-Cov-2

Enzo Biochem, Inc. to Launch Monkeypox Testing Services This Week

Enzo Biochem, Inc. Announces Executive Changes

Independent Director recently bought US$264k worth of stock

Enzo Biochem: Activist Pressure Could Finally Lead To A Company Sale

Independent Director recently bought US$276k worth of stock

Third quarter 2022 earnings released: US$0.10 loss per share (vs US$0.041 profit in 3Q 2021)

Enzo Biochem, Inc. to Report Q3, 2022 Results on Jun 09, 2022

Is Enzo Biochem (NYSE:ENZ) Using Debt In A Risky Way?

High number of new and inexperienced directors

Enzo Biochem Announces New York State Department of Health Approval of HPV Molecular Diagnostic Test

Enzo Biochem, Inc., Annual General Meeting, Apr 08, 2022

Enzo Biochem, Inc., Annual General Meeting, Apr 08, 2022

Enzo Biochem, Inc. Appoints David Bench and Kara Cannon to New Executive Management Positions

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Enzo Biochem, Inc. Announces Resignation of Barry Weiner as President, Effective April 19, 2022

High number of new and inexperienced directors

Less than half of directors are independent

Insider recently bought US$2.5m worth of stock

Is Enzo Biochem (NYSE:ENZ) A Risky Investment?

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider recently bought US$1.5m worth of stock

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS US$0.16 (vs US$0.60 loss in FY 2020)

Insider recently bought US$2.5m worth of stock

Health Check: How Prudently Does Enzo Biochem (NYSE:ENZ) Use Debt?

Enzo Biochem, Inc.(NYSE:ENZ) dropped from Russell 3000E Value Index

Third quarter 2021 earnings released: EPS US$0.041 (vs US$0.21 loss in 3Q 2020)

Enzo Biochem, Inc. Rejects Elazar Rabbani’s Previous Tender of Resignation as a Director

Second quarter 2021 earnings released: EPS US$0.048 (vs US$0.16 loss in 2Q 2020)

Enzo Biochem, Inc. Announces Resignation of Elazar Rabbani as CEO

Enzo Announces Its Genflex Molecular Test Detects Current Covid-19 Variants

Enzo Biochem, Inc. to Report Q2, 2021 Results on Mar 15, 2021

Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?

New 90-day high: US$3.25

Enzo Biochem, Inc. Announces Issuance of U.S. Patent for Polyclonal Antibodies Against Osteoporosis Drug Target Sclerostin

Is Enzo Biochem, Inc. (NYSE:ENZ) Popular Amongst Insiders?

Enzo Biochem's Board of Directors Forms New Corporate Development and Planning & Succession Committees

If You Had Bought Enzo Biochem's (NYSE:ENZ) Shares Three Years Ago You Would Be Down 66%

Enzo Biochem Receives FDA Emergency Use Authorization for Testing Pooled Samples on Three Platforms Including company’s GENFLEX™ Proprietary System for Detection of Coronavirus SARS-Cov-2

New 90-day high: US$2.66